Dr. Borgman is a highly accomplished CMO, business executive, scientific advisor, and board director with over 20 years of experience in clinical development and oncology-hematology drug approvals. She has led teams to successful approvals of several oncology assets, including recombinant asparaginase and cabozantinib. Dr. Borgman has a broad network and depth of regulatory interactions, enabling her to quickly synthesize the competitive landscape and collaborate with key stakeholders to forge a strategic path forward in a complex landscape. She has a strong core competency in hematology-oncology drug development and has led companies through growth phases at every stage in her career.